Table 2 Characteristics of response and progression in all patients
| Â | N (%) |
|---|---|
Primary resistance | |
 Yes | 38 (42%) |
 No | 52 (58%) |
New or existing lesion at progression | |
 New | 31 (34%) |
 Existing | 29 (32%) |
Additional treatment post ICI (n = 53, 58%) | 53 (58%) |
 VEGFR2 TKI containing therapy (n = 39, 74%) | 39 (74%) |
  Cabozantinib | 17 (32%) |
  Axitinib | 9 (17%) |
  VEGFR2 TKI + ICI | 6 (11%) |
  Lenvatinib + everolimus | 2 (5%) |
  Sunitinib | 2 (4%) |
  Lenvatinib | 1 (2%) |
  Pazopanib | 1 (2%) |
  Sorafenib | 1 (2%) |
  Clinical trial, other | 8 (15%) |
  Other (radiation only, hospice) | 3 (6%) |
  Everolimus | 2 (4%) |
  Nivolumab + ipilimumab | 1 (2%) |
Immune-related adverse events (irAE) | |
 No | 66 (73%) |
Type of irAEs | |
 Colitis | 8 (33%) |
 Pneumonitis | 5 (21%) |
 Hepatitis | 3 (13%) |
 Dermatitis | 3 (12%) |
irAEs causing treatment discontinuation | |
 Yes | 13 (54%) |